|
|
|
|
LEADER |
01708nam a22003015i 4500 |
001 |
000285604 |
005 |
20210511143956.0 |
007 |
cr nn 008mamaa |
008 |
110429s2011 xxu| s |||| 0|eng d |
020 |
|
|
|a 9781441984357
|
024 |
7 |
|
|a 10.1007/978-1-4419-8435-7
|2 doi
|
040 |
|
|
|a Sistema de Bibliotecas del Tecnológico de Costa Rica
|
245 |
1 |
0 |
|a Hedgehog signaling activation in human cancer and its clinical implications /
|c edited by Jingwu Xie.
|
250 |
|
|
|a 1st ed. 2011.
|
260 |
# |
# |
|a New York, NY :
|b Springer New York :
|b Imprint: Springer,
|c 2011.
|
300 |
|
|
|a IX, 217 p. :
|b online resource.
|
336 |
|
|
|a text
|b txt
|2 rdacontent
|
337 |
|
|
|a computer
|b c
|2 rdamedia
|
338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
505 |
0 |
|
|a Overview of hedgehog signaling pathway -- Regulation of Hh morphogene gradient -- Smoothened Signaling through a G-protein Effector Network.- Kinases and phosphatases in hedgehog signaling -- Signaling Cross-talk of Oncogenic KRAS and Hedgehog Pathways in Pancreatic Cancer.- Crosstalks between PKC and hedgehog signaling.- Activation of Hh signaling in human cancer.- Hedgehog signaling in pediatric brain tumors -- Hedgehog Signaling in Mammary Gland Development and Breast Cancer -- Hedgehog signaling and cancer therapeutic resistance.- Small-molecule Inhibitors of the Hedgehog Pathway.- Cyclopamine and its derivatives for cancer therapeutics.-.
|
650 |
|
0 |
|a Cancer research.
|
650 |
|
0 |
|a Pharmacology.
|
650 |
1 |
4 |
|a Cancer Research.
|
650 |
2 |
4 |
|a Pharmacology/Toxicology.
|
700 |
1 |
|
|a Xie, Jingwu.
|e editor.
|
710 |
2 |
|
|a SpringerLink (Online service)
|
773 |
0 |
|
|t Springer eBooks
|
900 |
|
|
|a Libro descargado a ALEPH en bloque (proveniente de proveedor)
|